CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
i
Naloxone Use During Pregnancy – Data from 26 U.S. Jurisdictions, 2019-2020
-
Nov-Dec 2024
-
-
Source: J Addict Med. 18(6):711-714
[PDF-164.82 KB]
Details:
-
Alternative Title:J Addict Med
-
Personal Author:
-
Description:Objectives:
We aimed to determine the prevalence of self-reported naloxone use during pregnancy among people in the U.S. with a recent live birth. A secondary objective was to characterize people at increased risk for overdose who did and did not use naloxone.
Methods:
We analyzed data from the Pregnancy Risk Assessment Monitoring System from 26 U.S. jurisdictions that conducted an opioid supplement survey from 2019 through 2020. Respondents with increased risk of experiencing an opioid overdose were identified based on self-reported use of illicit amphetamines, heroin, cocaine, or receiving medication for opioid use disorder (MOUD) during pregnancy. Weighted prevalence estimates and 95% confidence intervals were calculated for reported naloxone use at any point during pregnancy among people with an increased risk of overdose.
Results:
Naloxone use during pregnancy was reported by < 1% of the overall study population (unweighted N=88/34,528). Prevalence of naloxone use was 5.0% (95% CI: 0.0-10.6) among respondents who reported illicit amphetamine use, 15.2% (1.8-28.6) among those who reported heroin use, and 17.6% (0.0-38.1) among those who reported cocaine use. Naloxone use was 14.5% (8.4-20.6) among those who reported taking MOUD. Among people with increased risk of overdose, no significant differences in naloxone use were observed by age, race/ethnicity, education level, residential metropolitan status, or insurance status.
Conclusions:
Prevalence of naloxone use among people with an increased risk of overdose during pregnancy ranged from 5.0% to 17.6%. Access to naloxone, overdose prevention education, and treatment for substance use disorders may help reduce morbidity and mortality.
-
Subjects:
-
Keywords:
-
Source:
-
Pubmed ID:38912696
-
Pubmed Central ID:PMC11537837
-
Document Type:
-
Funding:
-
Volume:18
-
Issue:6
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type:
